Shares of GSK plc traded lower during the early session in London on Monday, March 2, 2026, moving in tandem with a broader decline in the UK equity market. The pharmaceutical giant's stock was down approximately 1.1%, reaching a price of 2,177 pence by 0823 GMT after fluctuating between 2,172 and 2,194 pence.
Broader Market Pressure
The pullback occurred against a backdrop of significant market volatility. The benchmark FTSE 100 index was down roughly 0.7%, with sector peer AstraZeneca also trading lower. The primary catalyst for the widespread risk-off sentiment was a sharp increase in crude oil prices following renewed military conflict in the Middle East. The fighting disrupted critical shipping lanes around the Strait of Hormuz, a vital chokepoint for global oil supply.
This geopolitical shock prompted investors to seek safer assets and revived anxieties about persistent inflationary pressures. "Financial markets are recognizing the severity of the conflict, but current signals suggest this is being viewed as a geopolitical event rather than a systemic financial crisis," commented Priyanka Sachdeva, a senior market analyst at Phillip Nova.
GSK's Buyback Program Advances
Amid the market turbulence, GSK provided an update on its ongoing share repurchase initiative. The company disclosed that on February 27, it repurchased 430,000 of its ordinary shares through the investment bank BNP Paribas. The transaction was executed at an average weighted price of 2,179.36 pence per share. These repurchased shares will be held in treasury.
This latest activity is part of a larger program. Since February 17, GSK has bought back a total of 4,136,000 shares. The company now holds 244,027,094 shares in its treasury, representing approximately 5.99% of its total voting rights. Treasury shares are those a company buys back and retains rather than retiring, a move that can increase earnings per share over time by reducing the number of shares outstanding.
Near-Term Market Drivers
Analysts suggest that trading in the coming sessions will likely be dominated by macroeconomic factors rather than individual company stories. The market's attention is divided between ongoing oil price volatility, upcoming U.S. economic data including manufacturing surveys and labor market reports, and the trajectory of interest rates. A prolonged period of elevated energy costs poses a risk to GSK and the broader market, as it could entrench inflation expectations and pressure equity valuations. Even defensive stocks like pharmaceuticals can face selling pressure in volatile markets as investors raise cash for liquidity.
Upcoming Regulatory Catalyst
For GSK specifically, the next significant company-specific event is a regulatory milestone. The U.S. Food and Drug Administration has set a target date of March 24, 2026, to decide on the marketing application for linerixibat. The drug is intended to treat cholestatic pruritus, a debilitating itch, in patients with primary biliary cholangitis, a chronic liver disease.
This decision represents a key near-term catalyst for the company's pipeline. "The FDA's acceptance of this filing is an important milestone for patients and our research efforts," stated Kaivan Khavandi, a senior vice president in GSK's research and development division, when the regulatory review commenced. Linerixibat is not yet approved for use in any market.
Investors will be monitoring the FDA's decision closely, as a positive outcome could provide a new growth avenue for GSK, while the broader market will continue to weigh geopolitical developments and their impact on inflation and monetary policy.
